Vidac Pharma
Targeting a metabolic master regulator of proliferation
to deliver novel oncology and dermatology solutions
to deliver novel oncology and dermatology solutions
Vidac Pharma
Targeting a metabolic master regulator of proliferation
to deliver novel oncology and dermatology solutions
to deliver novel oncology and dermatology solutions
Vidac Pharma
Targeting a metabolic master regulator of proliferation
to deliver novel oncology and dermatology solutions
to deliver novel oncology and dermatology solutions
As the incidence of both non-melanoma and melanoma skin cancers has been increasing over the past decades, better treatment modalities are needed.
VDA-1102 ointment is the FIRST in a new class of drugs that selectively targets malignant skin cancer cells with minimal effects on surrounding healthy skin.
HK2 has a vital role in cancer metabolism. Vidac is creating innovative therapies for people suffering from a range of oncology and dermatology ailments.
Pipeline
Vidac has built a portfolio of novel product candidates that target significant unmet medical needs in oncology and dermatology.
Therapeutic Areas
Vidac is creating innovative therapies for people suffering from a range of oncologic and dermatologic medical conditions.